Quality assurance target for community-based breast cancer screening in China: a model simulation

BMC Cancer

Table 1 Clinical and cost parameter estimates for the base case and sensitivity analyses

Parameter				Ref.
The distribution of invasive Breast Cancer stages	Screen	No screen	Distribution	[43, 44]
Stage I	0.360	0.203	Dirichlet [15]
Stage II	0.490	0.541
Stage III	0.144	0.237
Stage IV	0.006	0.019
Screen method test characteristics	Sensitivity	Specificity
CBE	0.431 (0.335–0.528)	0.994 (0.994–0.995)	Uniform [15]	[18]
A series of CBE, MAM and ultrasound connection	0.330 (0.238–0.422)	0.999 (0.999–1.000)
A series of CBE and MAM connection	0.360 (0.256–0.454)	0.999 (0.999–1.000)
Stage progression transition probabilities				[15]
Stage I-IV	0.01		Invariant [15]
Stage II-IV	0.08
Stage III-IV	0.21
Compliance rate	0.5–1		Uniform [15]	[18]
Attend rate	0.3–1		Uniform [15]	[18]
Transition probabilities of breast cancer(Rate per 100,000 women)	All-cause mortality		Breast cancer mortality
35-	53.86		3.78	[17]
40-	95.25		6.90
45-	149.34		12.66
50-	212.43		16.57
55-	348.31		22.74
60-	604.84		23.49
65-	1030.55		23.95
70-	2036.08		25.86
75-	3783.51		31.57
80-	6997.94		40.36
> 85	13,602.90		48.85
Cost components^a	Cost
Management cost and cost for CBE	$4.3			[20]
Cost of evaluating abnormal CBE
MAM	$29.0			[20]
USG	$10.2
Cost of biopsy	$174.3
Treatment and follow-up	Treatment cost		Follow-up cost
DCIS	$1607.2		$1712.7	[21, 22]
Stage I	$1940.7		$4022.8
Stage II	$1960.1		$5653.7
Stage III	$1902.9		$6481.7
Stage IV	$1566.7		$4584.5

Abbreviations: CBE; Clinical breast examination, MAM; Mammography, USG; Ultrasonography, DCIS; Ductal carcinoma in situ
^aExchange rate 6.8858 RMB = 1 US Dollar

ISSN: 1471-2407